GlassScriptPhysician profile
Nicolas A Hernandez Sanabria
NPI 1275637332
$1,655.43
in general payments reported to CMS, 2019-2025
18 companies · $807 in 2025
The $807 reported for 2025 was more than what 79% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $57.45 · 2021: $51.68 · 2022: $190 · 2023: $120 · 2024: $194 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $487.98 | 2019-2025 | Quillichew Er, Dyanavel Xr, Quillivant |
| Abbvie INC. | $246.24 | 2022-2025 | |
| Sobi, INC | $150.01 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $149.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $140.56 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $71.45 | 2024 | Cobenfy |
| Sanofi-Aventis U.S. LLC | $66.52 | 2025 | |
| Mallinckrodt Hospital Products INC. | $51.68 | 2021 | |
| Incyte Corporation | $49.31 | 2025 | Jakafi, Monjuvi, Pemazyre |
| Genmab U.S., INC. | $39.31 | 2024 | Epkinly |
| Actelion Pharmaceuticals US, INC. | $37.45 | 2020 | |
| Pbg Puerto Rico LLC | $36.74 | 2022-2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 2025 | Jaypirca |
| Glaxosmithkline, LLC. | $24.78 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.44 | 2024 | Ultomiris |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.00 | 2020 | |
| Caris Mpi, INC. | $19.96 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $15.72 | 2025 | Tavalisse, Gavreto, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Hernandez Sanabria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.